delivery. Other single spontaneous delivery
Conditions
Interventions
Intervention 1: Capsules 250 mg of the drug (saffron) every 2 hours and up to 3 doses, the intensity of uterine contractions and the progress of labor is consumed orally by the research unit. Interve
Placebo
Capsules 250 mg of the drug (saffron) every 2 hours and up to 3 doses, the intensity of uterine contractions and the progress of labor is consumed orally by the research unit
Capsules 250 mg of the pelacebo every 2 hours and up to 3 doses, the intensity of uterine contractions and the progress of labor is consumed orally by the research unit
Sponsors
Research Council of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Completing the written informed consent to participate in the study?age of 18-35 years; body mass index of 19.5- 30;gestational age of 37-42 weeks; having no history of pregnancy more than 20 weeks of gestation; singleton pregnancy; cervical dilatation of 3-4 cm; cephalic presentation. Exclusion criteria: using any herbal drug during the past 48 hours; addiction or using a variety of tobacco and alcohol; maternal pregnancy complications (preeclampsia, bleeding during pregnancy, threat to abortion, premature rupture of fetus membranes more than 12 hours before admission of mother), having or history of any systemic disease (diabetes, hypertension, heart and kidney disease, etc), history of mental disorder, speaking, hearing and mental disorder, disproportion of maternal pelvic with fetal head; estimated fetal weight less than 2500 g and more than 4000 g (according to Johnson rules); fetal heart rate abnormalities; any abnormalities in the fetus (based on sonography; obstetric problems; multiple pregnancy; previous surgery on the uterus; cervix and delivery canal; cesarean indication; allergic reaction to the saffron
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity of labor. Timepoint: 1 hour intervals during the intervention. Method of measurement: Pain intensity using a visual pain scale.;Duration of the active phase of labor first stage. Timepoint: 1-2 hour intervals during the intervention. Method of measurement: During the active phase of labor and vaginal exam registration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Uterine contractions. Timepoint: During each 30-minute intervention. Method of measurement: Tocodynamomtr device and touch the hand. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSedigheh Ahmadi
Mashhad University of Medical Sciences
Outcome results
None listed